Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/6258
Title: Pathophysiological rationale for the use of a new amino acid mixture for liver damage
Authors: Z. A Sayfutdinova, G. Y Xashimova, B. N Yusupov, X. G Muhammadiev, G. E Shomansurova
Keywords: heliotrin intoxication; inflammation biomarkers; amino acid mixture; Infesol experimental animals.
Issue Date: Jan-2023
Publisher: Galaxy international interdisciplinary research journal (GIIRJ)
Series/Report no.: Vol.;11
Abstract: determination of the pathophysiological validity of the use of the new amino acid mixture for damage to the liver.Materials methods. Acute heliotrin intoxication is reproduced by single administration of rats subcutaneous sub-lethal doses of heliotrin, prepared at the rate of 40 mg per 100 g of body weight. Toxic hepatitis is reproduced by subcutaneous administration of heliotrin. Results. During the reproduction of experimental toxic hepatitis by introducing heliotrin, it was found that the HIF-1 content was on average 0.101667 ± 0.0022 ng /l. In blood plasma, the average HIF-1 was 0.2136 ± 0.0066 ng / L. Such indicators are explained by the effect of heliotrin on the liver and, above all, on hepatocytes, in which mitochondria are experiencing an oxygen deficiency. Thus, HIF-1 acts as an early biomarker of oxygen tissue deficiency and since it causes angiogenesis, the strengthening of this gene in experimental animals with ischemia can contribute to the proliferation of vessels necessary for oxygenation. Conclusions: The developed aminoacid mixture in terms of the effectiveness of the impact on the development and course of experimental toxic hepatitis surpasses traditional methods of treatment, which is proved by the study
URI: http://repository.tma.uz/xmlui/handle/1/6258
ISSN: (E): 2347-6915
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
document (5).pdf195.92 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.